Neuropathological findings revealed a tau phosphorylation and deposition in the hypothalamus and tegmentum of the brainstem.[2] The clinical manifestation of anti-IgLON5 disease seems to be heterogeneous, mostly including sleep dysfunction, bulbar symptoms, progressive supranuclear palsy-like syndrome, cognitive impairment, and a variety of movement disorders. Here, IGLON5 is linked to movement disorder.